FDA paints chaotic off-label picture

WASHINGTON - Confusion over the status of regulations on the dissemination of data about off-label uses of approved products has created a legal limbo in which manufacturers of drugs, biologics and devices are adopting diverse strategies. Some have submitted off-label information to FDA for review and approval prior to dissemination, others have cited a federal judge's ruling as authority for disseminating information with accompanying disclosures, and others are completely ignoring the agency, according to an affidavit filed by the FDA last week.

In July 1998, Judge

Read the full 855 word article

How to gain access

Continue reading with a
two-week free trial.